According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …

Background: While long-acting injectable antipsychotics (LAIs) are hoped to reduce high
relapse rates in schizophrenia, recent randomized controlled trials (RCTs) challenged the …

Importance The doses of antipsychotic drugs needed for relapse prevention in
schizophrenia is a debated issue. Objective To examine dose-response findings in a meta …

Background Relapse prevention with antipsychotic drugs compared with placebo in patients
with schizophrenia has not been sufficiently addressed by previous systematic reviews. We …

Background Schizophrenia is a common, severe, and usually chronic disorder. Maintenance
treatment with antipsychotic drugs can prevent relapse but also causes side-effects. We …

Objective As psychopathology and social functioning can worsen with repeated psychotic
episodes in schizophrenia, relapse prevention is critical. Because high nonadherence rates …

Few controlled trials compared second-generation antipsychotics (SGAs) with first-
generation antipsychotics (FGAs) regarding relapse prevention in schizophrenia. We …

Background Dose reduction of antipsychotic maintenance treatment in individuals with
schizophrenia could be desirable to minimise adverse effects, but evidence for this strategy …

Background Most individuals with schizophrenia-spectrum disorders have relapses, which
increase the risk of morbidity and mortality. Because non-adherence to antipsychotic …

Background Although antipsychotic maintenance treatment is widely recommended to
prevent relapse in chronic psychoses, evidence-based guidelines do not provide clear …